<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32633852</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1750-3639</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Brain pathology (Zurich, Switzerland)</Title><ISOAbbreviation>Brain Pathol</ISOAbbreviation></Journal><ArticleTitle>Neuropathological profile of long-duration amyotrophic lateral sclerosis in military Veterans.</ArticleTitle><Pagination><StartPage>1028</StartPage><EndPage>1040</EndPage><MedlinePgn>1028-1040</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bpa.12876</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder affecting both the upper and lower motor neurons. Although ALS typically leads to death within 3 to 5&#xa0;years after initial symptom onset, approximately 10% of patients with ALS live more than 10&#xa0;years after symptom onset. We set out to determine similarities and differences in clinical presentation and neuropathology in persons with ALS with long vs. those with standard duration. Participants were United States military Veterans with a pathologically confirmed diagnosis of ALS (n&#xa0;=&#xa0;179), dichotomized into standard duration (&lt;10&#xa0;years) and long-duration (&#x2265;10&#xa0;years). The ALS Functional Rating Scale-Revised (ALSFRS-R) was administered at study entry and semi-annually thereafter until death. Microglial density was determined in a subset of participants. long-duration ALS occurred in 76 participants (42%) with a mean disease duration of 16.3&#xa0;years (min/max&#xa0;=&#xa0;10.1/42.2). Participants with long-duration ALS were younger at disease onset (P&#xa0;=&#xa0;0.002), had a slower initial ALS symptom progression on the ALSFRS-R (P&#xa0;&lt;&#xa0;0.001) and took longer to diagnose (P&#xa0;&lt;&#xa0;0.002) than standard duration ALS. Pathologically, long-duration ALS was associated with less frequent TDP-43 pathology (P&#xa0;&lt;&#xa0;0.001). Upper motor neuron degeneration was similar; however, long-duration ALS participants had less severe lower motor neuron degeneration at death (P&#xa0;&lt;&#xa0;0.001). In addition, the density of microglia was decreased in the corticospinal tract (P&#xa0;=&#xa0;0.017) and spinal cord anterior horn (P&#xa0;=&#xa0;0.009) in long-duration ALS. Notably, many neuropathological markers of ALS were similar between the standard and long-duration groups and there was no difference in the frequency of known ALS genetic mutations. These findings suggest that the lower motor neuron system is relatively spared in long-duration ALS and that pathological progression is likely slowed by as yet unknown genetic and environmental modifiers.</AbstractText><CopyrightInformation>Published 2020. This article is a U.S. Government work and is in the public domain in the USA.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spencer</LastName><ForeName>Keith R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>VA Boston Healthcare System, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foster</LastName><ForeName>Zachariah W</ForeName><Initials>ZW</Initials><AffiliationInfo><Affiliation>VA Boston Healthcare System, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rauf</LastName><ForeName>Nazifa Abdul</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>VA Boston Healthcare System, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guilderson</LastName><ForeName>Latease</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>VA Boston Healthcare System, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Derek</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>VA Boston Healthcare System, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Averill</LastName><ForeName>James G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Southern Arizona VA Healthcare System, Tucson, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Sean E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Southern Arizona VA Healthcare System, Tucson, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robey</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Southern Arizona VA Healthcare System, Tucson, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cherry</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0002-1257-981X</Identifier><AffiliationInfo><Affiliation>VA Boston Healthcare System, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Victor E</ForeName><Initials>VE</Initials><AffiliationInfo><Affiliation>VA Boston Healthcare System, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Veterans Affairs Medical Center, Bedford, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huber</LastName><ForeName>Bertrand R</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>VA Boston Healthcare System, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Veterans Affairs Medical Center, Bedford, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKee</LastName><ForeName>Ann C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>VA Boston Healthcare System, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Veterans Affairs Medical Center, Bedford, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil W</ForeName><Initials>NW</Initials><AffiliationInfo><Affiliation>VA Boston Healthcare System, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brady</LastName><ForeName>Christopher B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>VA Boston Healthcare System, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Aging, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stein</LastName><ForeName>Thor D</ForeName><Initials>TD</Initials><Identifier Source="ORCID">0000-0001-6954-4477</Identifier><AffiliationInfo><Affiliation>VA Boston Healthcare System, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Veterans Affairs Medical Center, Bedford, MA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 AG057768</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>BX003063</GrantID><Agency>U.S. Department of Veterans Affairs</Agency><Country/></Grant><Grant><GrantID>RF1AG054156</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX003063</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 CX001038</GrantID><Acronym>CX</Acronym><Agency>CSRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054156</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX002466</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>BX002466</GrantID><Agency>U.S. Department of Veterans Affairs</Agency><Country/></Grant><Grant><GrantID>I01-CX001038</GrantID><Agency>U.S. Department of Veterans Affairs</Agency><Country/></Grant><Grant><GrantID>R56 AG057768</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG13846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Brain Pathol</MedlineTA><NlmUniqueID>9216781</NlmUniqueID><ISSNLinking>1015-6305</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011712" MajorTopicYN="N">Pyramidal Tracts</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014728" MajorTopicYN="N">Veterans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">long-duration</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">military Veterans</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">neuropathology</Keyword><Keyword MajorTopicYN="N">survival</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32633852</ArticleId><ArticleId IdType="mid">NIHMS1727995</ArticleId><ArticleId IdType="pmc">PMC8018169</ArticleId><ArticleId IdType="doi">10.1111/bpa.12876</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Chalabi A, Hardiman O (2013) The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 9:617&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Jones A, Troakes C, King A, Al-Sarraj S, van den Berg LH (2012) The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol 124:339&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">22903397</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexianu ME, Kozovska M, Appel SH (2001) Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 57:1282&#x2013;1289.</Citation><ArticleIdList><ArticleId IdType="pubmed">11591849</ArticleId></ArticleIdList></Reference><Reference><Citation>Alosco ML, Stein TD, Tripodis Y, Chua AS, Kowall NW, Huber BR et al (2019) Association of white matter rarefaction, arteriolosclerosis, and tau with dementia in chronic traumatic encephalopathy. JAMA Neurol 76:1298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6686769</ArticleId><ArticleId IdType="pubmed">31380975</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshikho MJ, Zurcher NR, Loggia ML, Cernasov P, Reynolds B, Pijanowski O et al (2018) Integrated magnetic resonance imaging and [(11) C]-PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis. Ann Neurol 83:1186&#x2013;1197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6105567</ArticleId><ArticleId IdType="pubmed">29740862</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur KC, Calvo A, Price TR, Geiger JT, Chio A, Traynor BJ (2016) Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun 7:12408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4987527</ArticleId><ArticleId IdType="pubmed">27510634</ArticleId></ArticleIdList></Reference><Reference><Citation>Beard JD, Engel LS, Richardson DB, Gammon MD, Baird C, Umbach DM et al (2017) Military service, deployments, and exposures in relation to amyotrophic lateral sclerosis survival. PLoS One 12:e0185751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5634564</ArticleId><ArticleId IdType="pubmed">29016608</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigio EH (2008) Update on recent molecular and genetic advances in frontotemporal lobar degeneration. J Neuropathol Exp Neurol 67:635&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2761710</ArticleId><ArticleId IdType="pubmed">18596549</ArticleId></ArticleIdList></Reference><Reference><Citation>Blauwendraat C, Faghri F, Pihlstrom L, Geiger JT, Elbaz A, Lesage S et al (2017) NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases. Neurobiol Aging 57:e9&#x2013;e13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5534378</ArticleId><ArticleId IdType="pubmed">28602509</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady CB, Trevor KT, Stein TD, Deykin EY, Perkins SD, Averill JG et al (2013) The Department of Veterans Affairs Biorepository Brain Bank: a national resource for amyotrophic lateral sclerosis research. Amyotroph Lateral Scler Frontotemporal Degener 14:591&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pubmed">23971854</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Arai K, Del Tredici K, Toledo JB, Robinson JL, Lee EB et al (2014) TDP&#x2010;43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. Acta Neuropathol 128:423&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4384652</ArticleId><ArticleId IdType="pubmed">24916269</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M et al (2013) Stages of pTDP&#x2010;43 pathology in amyotrophic lateral sclerosis. Ann Neurol 74:20&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Toledo JB, Van Deerlin VM, Elman L, McCluskey L, Lee VM, Trojanowski JQ (2012) Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS One 7:e39216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375234</ArticleId><ArticleId IdType="pubmed">22720079</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A (2017) Amyotrophic lateral sclerosis. N Engl J Med 377:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownell B, Oppenheimer DR, Hughes JT (1970) The central nervous system in motor neurone disease. J Neurol Neurosurg Psychiatry 33:338&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC493478</ArticleId><ArticleId IdType="pubmed">5431724</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ et al (2007) Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 114:5&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827877</ArticleId><ArticleId IdType="pubmed">17579875</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N (1997) Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials. J Neurol Sci 152(Suppl 1):S1&#x2013;S9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9419047</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A (1999) The ALSFRS&#x2010;R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherry JD, Tripodis Y, Alvarez VE, Huber B, Kiernan PT, Daneshvar DH et al (2016) Microglial neuroinflammation contributes to tau accumulation in chronic traumatic encephalopathy. Acta Neuropathol Commun 4:112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5084333</ArticleId><ArticleId IdType="pubmed">27793189</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Bottacchi E, Buffa C, Mutani R, Mora G, Parals (2006) Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry 77:948&#x2013;950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077622</ArticleId><ArticleId IdType="pubmed">16614011</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Calvo A, Moglia C, Mazzini L, Mora G, Group Ps (2011) Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 82:740&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">21402743</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Logroscino G, Hardiman O, Swingler R,Mitchell D, Beghi E et al (2009) Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 10:310&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, White LA (2013) Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41:118&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Tauber C, Vercoullie J, Arlicot N, Prunier C, Praline J et al (2012) Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One 7:e52941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534121</ArticleId><ArticleId IdType="pubmed">23300829</ArticleId></ArticleIdList></Reference><Reference><Citation>Cykowski MD, Powell SZ, Peterson LE, Appel JW, Rivera AL, Takei H et al (2017) Clinical significance of TDP&#x2010;43 neuropathology in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 76:402&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5901081</ArticleId><ArticleId IdType="pubmed">28521037</ArticleId></ArticleIdList></Reference><Reference><Citation>Department of Veterans A (2009) Presumption of service connection for amyotrophic lateral sclerosis. Final rule. Fed Regist 74:57072&#x2013;57074.</Citation><ArticleIdList><ArticleId IdType="pubmed">20166277</ArticleId></ArticleIdList></Reference><Reference><Citation>Diagnosis ETFo , Management of Amyotrophic Lateral S , Andersen PM, Abrahams S, Borasio GD, de Carvalho M et al (2012) EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)&#x2013;revised report of an EFNS task force. Eur J Neurol 19:360&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">21914052</ArticleId></ArticleIdList></Reference><Reference><Citation>Doorn KJ, Moors T, Drukarch B, van de Berg W, Lucassen PJ, van Dam AM (2014) Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients. Acta Neuropathol Commun 2:90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4224021</ArticleId><ArticleId IdType="pubmed">25099483</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisen A, Schulzer M, MacNeil M, Pant B, Mak E (1993) Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve 16:27&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">8423829</ArticleId></ArticleIdList></Reference><Reference><Citation>Eng LF, Ghirnikar RS, Lee YL (2000) Glial fibrillary acidic protein: GFAP-thirty-one years (1969&#x2013;2000). Neurochem Res 25:1439&#x2013;1451.</Citation><ArticleIdList><ArticleId IdType="pubmed">11059815</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt JI, Appel SH (1990) IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch Neurol 47:1210&#x2013;1216.</Citation><ArticleIdList><ArticleId IdType="pubmed">2122877</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt JI, Tajti J, Appel SH (1993) Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch Neurol 50:30&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">8093428</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatima M, Tan R, Halliday GM, Kril JJ (2015) Spread of pathology in amyotrophic lateral sclerosis: assessment of phosphorylated TDP&#x2010;43 along axonal pathways. Acta Neuropathol Commun 3:47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4517552</ArticleId><ArticleId IdType="pubmed">26216351</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Cheng B, Katz IB, Pinto M, Hays AP, Mitsumoto H, Rowland LP (2006) The natural history of primary lateral sclerosis. Neurology 66:647&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pubmed">16534101</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenfield JG, Love S, Louis DN, Ellison D (2008) Greenfield's neuropathology, 8th edn. London: Hodder Arnold.</Citation></Reference><Reference><Citation>Haley RW (2003) Excess incidence of ALS in young Gulf War veterans. Neurology 61:750&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">14504316</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall ED, Oostveen JA, Gurney ME (1998) Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 23:249&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">9633809</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W et al (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Primers 3:17085.</Citation><ArticleIdList><ArticleId IdType="pubmed">29052611</ArticleId></ArticleIdList></Reference><Reference><Citation>Haverkamp LJ, Appel V, Appel SH (1995) Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 118 (Pt 3):707&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">7600088</ArticleId></ArticleIdList></Reference><Reference><Citation>Holness CL, Simmons DL (1993) Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood 81:1607&#x2013;1613.</Citation><ArticleIdList><ArticleId IdType="pubmed">7680921</ArticleId></ArticleIdList></Reference><Reference><Citation>Horner RD, Kamins KG, Feussner JR, Grambow SC, Hoff-Lindquist J, Harati Y et al (2003) Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. Neurology 61:742&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">14504315</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman MH, de Jong SW, van Doormaal PT, Weinreich SS, Schelhaas HJ, van der Kooi AJ et al (2011) Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology. J Neurol Neurosurg Psychiatry 82:1165&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pubmed">21622937</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito D, Imai Y, Ohsawa K, Nakajima K, Fukuuchi Y, Kohsaka S (1998) Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res 57:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9630473</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwanaga K, Hayashi S, Oyake M, Horikawa Y, Hayashi T, Wakabayashi M et al (1997) Neuropathology of sporadic amyotrophic lateral sclerosis of long duration. J Neurol Sci 146:139&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">9077510</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssens J, Wils H, Kleinberger G, Joris G, Cuijt I, Ceuterick-de Groote C et al (2013) Overexpression of ALS-associated p. M337V human TDP&#x2010;43 in mice worsens disease features compared to wild-type human TDP&#x2010;43 mice. Mol Neurobiol 48:22&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3718993</ArticleId><ArticleId IdType="pubmed">23475610</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara JH, Genc B, Stanford MJ, Pytel P, Roos RP, Weintraub S et al (2017) Evidence for an early innate immune response in the motor cortex of ALS. J Neuroinflammation 14:129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5485686</ArticleId><ArticleId IdType="pubmed">28651542</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasarkis EJ, Dominic K, Oddone EZ (2004) The National Registry of Veterans with Amyotrophic Lateral Sclerosis: Department of Veterans Affairs Cooperative Studies Program (CSP) #500a. Amyotroph Lateral Scler Other Motor Neuron Disord 5(Suppl 1):129&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">15512895</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasarskis EJ, Lindquist JH, Coffman CJ, Grambow SC, Feussner JR, Allen KD et al (2009) Clinical aspects of ALS in Gulf War veterans. Amyotroph Lateral Scler 10:35&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">18792848</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P, Levy G, Montes J, Buchsbaum R, Barsdorf AI, Battista V et al (2007) Excellent inter&#x2010;rater, intra-rater, and telephone-administered reliability of the ALSFRS&#x2010;R in a multicenter clinical trial. Amyotroph Lateral Scler 8:42&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">17364435</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH et al (2005) The ALSFRSr predicts survival time in an ALS clinic population. Neurology 64:38&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642901</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamata T, Akiyama H, Yamada T, McGeer PL (1992) Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol 140:691&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886170</ArticleId><ArticleId IdType="pubmed">1347673</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WK, Liu X, Sandner J, Pasmantier M, Andrews J, Rowland LP, Mitsumoto H (2009) Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology 73:1686&#x2013;1692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2788803</ArticleId><ArticleId IdType="pubmed">19917992</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollewe K, Mauss U, Krampfl K, Petri S, Dengler R, Mohammadi B (2008) ALSFRS&#x2010;R score and its ratio: a useful predictor for ALS-progression. J Neurol Sci 275:69&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">18721928</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushner PD, Stephenson DT, Wright S (1991) Reactive astrogliosis is widespread in the subcortical white matter of amyotrophic lateral sclerosis brain. J Neuropathol Exp Neurol 50:263&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">2022968</ArticleId></ArticleIdList></Reference><Reference><Citation>Labra J, Menon P, Byth K, Morrison S, Vucic S (2016) Rate of disease progression: a prognostic biomarker in ALS. J Neurol Neurosurg Psychiatry 87:628&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">26152368</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao B, Zhao W, Beers DR, Henkel JS, Appel SH (2012) Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol 237:147&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4126417</ArticleId><ArticleId IdType="pubmed">22735487</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J et al (2010) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 119:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2799633</ArticleId><ArticleId IdType="pubmed">19924424</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, Baloh RH (2019) Inflammation in ALS/FTD pathogenesis. Acta Neuropathol 137:715&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W et al (2009) Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73:1227&#x2013;1233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764728</ArticleId><ArticleId IdType="pubmed">19822873</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM et al (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41:479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell JD, Borasio GD (2007) Amyotrophic lateral sclerosis. Lancet 369:2031&#x2013;2041.</Citation><ArticleIdList><ArticleId IdType="pubmed">17574095</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW et al (2012) National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 123:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy D, Kato T, Kushner PD (1994) Reactive astrocytes are widespread in the cortical gray matter of amyotrophic lateral sclerosis. J Neurosci Res 38:336&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">7523689</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT et al (2006) Ubiquitinated TDP&#x2010;43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R et al (2018) Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron 97, 1268&#x2013;1283 e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishihira Y, Tan CF, Hoshi Y, Iwanaga K, Yamada M, Kawachi I et al (2009) Sporadic amyotrophic lateral sclerosis of long duration is associated with relatively mild TDP&#x2010;43 pathology. Acta Neuropathol 117:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">18923836</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishihira Y, Tan CF, Onodera O, Toyoshima Y, Yamada M, Morita T et al (2008) Sporadic amyotrophic lateral sclerosis: two pathological patterns shown by analysis of distribution of TDP&#x2010;43-immunoreactive neuronal and glial cytoplasmic inclusions. Acta Neuropathol 116:169&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">18481073</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Deng J, Jaffa M, Cudkowicz ME, Wills AM (2011) Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve 44:20&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4441750</ArticleId><ArticleId IdType="pubmed">21607987</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Karam C, Joyce N, Bedlack R, Carter GT (2015) Comprehensive rehabilitative care across the spectrum of amyotrophic lateral sclerosis. NeuroRehabilitation 37:53&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5223769</ArticleId><ArticleId IdType="pubmed">26409693</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastula DM, Coffman CJ, Allen KD, Oddone EZ, Kasarskis EJ, Lindquist JH et al (2009) Factors associated with survival in the National Registry of Veterans with ALS. Amyotroph Lateral Scler 10:332&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">19922120</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugliatti M, Parish LD, Cossu P, Leoni S, Ticca A, Saddi MV et al (2013) Amyotrophic lateral sclerosis in Sardinia, insular Italy, 1995&#x2013;2009. J Neurol 260:572&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pubmed">23052600</ArticleId></ArticleIdList></Reference><Reference><Citation>Pupillo E, Messina P, Logroscino G, Beghi E, Group S (2014) long&#x2010;term survival in amyotrophic lateral sclerosis: a population-based study. Ann Neurol 75:287&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">24382602</ArticleId></ArticleIdList></Reference><Reference><Citation>Saberi S, Stauffer JE, Schulte DJ, Ravits J (2015) Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants. Neurol Clin 33:855&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4628785</ArticleId><ArticleId IdType="pubmed">26515626</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanagi T, Yuasa S, Nakamura Y, Suzuki E, Aoki M, Warita H et al (2010) Appearance of phagocytic microglia adjacent to motoneurons in spinal cord tissue from a presymptomatic transgenic rat model of amyotrophic lateral sclerosis. J Neurosci Res 88:2736&#x2013;2746.</Citation><ArticleIdList><ArticleId IdType="pubmed">20648658</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer D, Cordera S, Cavalla P, Migheli A (1996) Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J Neurol Sci 139(Suppl):27&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">8899654</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter EL, Chen HJ, Shaw CE (2015) TDP&#x2010;43 proteinopathy and ALS: insights into disease mechanisms and therapeutic targets. Neurotherapeutics 12:352&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4404432</ArticleId><ArticleId IdType="pubmed">25652699</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B, Robberecht W (2014) The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol 10:661&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O (2003) Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996&#x2013;2000. J Neurol Neurosurg Psychiatry 74:1258&#x2013;1261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738639</ArticleId><ArticleId IdType="pubmed">12933930</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Cagnin A, Turkheimer FE, Miller CC, Shaw CE, Brooks DJ et al (2004) Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis 15:601&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">15056468</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, Robberecht W, Van Den Bosch L (2017) Modelling amyotrophic lateral sclerosis: progress and possibilities. Dis Model Mech 10:537&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5451175</ArticleId><ArticleId IdType="pubmed">28468939</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Berg JP, Kalmijn S, Lindeman E, Veldink JH, de Visser M, Van der Graaff MM et al (2005) Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology 65:1264&#x2013;1267.</Citation><ArticleIdList><ArticleId IdType="pubmed">16247055</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker DG, Lue LF (2015) Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains. Alzheimers Res Ther 7:56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4543480</ArticleId><ArticleId IdType="pubmed">26286145</ArticleId></ArticleIdList></Reference><Reference><Citation>Walt GS, Burris HM, Brady CB, Spencer KR, Alvarez VE, Huber BR et al (2018) Chronic traumatic encephalopathy within an amyotrophic lateral sclerosis brain bank cohort. J Neuropathol Exp Neurol 77:1091&#x2013;1100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6927868</ArticleId><ArticleId IdType="pubmed">30299493</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei QQ, Chen Y, Chen X, Cao B, Ou R, Zhang L et al (2018) Clinical and prognostic features of ALS/MND in different phenotypes-data from a hospital-based registry. Brain Res Bull 142:403&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">30232045</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisskopf MG, O'Reilly EJ, McCullough ML, Calle EE, Thun MJ, Cudkowicz M, Ascherio A (2005) Prospective study of military service and mortality from ALS. Neurology 64:32&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642900</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousef A, Robinson JL, Irwin DJ, Byrne MD, Kwong LK, Lee EB et al (2017) Neuron loss and degeneration in the progression of TDP&#x2010;43 in frontotemporal lobar degeneration. Acta Neuropathol Commun 5:68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5586052</ArticleId><ArticleId IdType="pubmed">28877758</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Gascon R, Miller RG, Gelinas DF, Mass J, Hadlock K et al (2005) Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol 159:215&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">15652422</ArticleId></ArticleIdList></Reference><Reference><Citation>Zotova E, Bharambe V, Cheaveau M, Morgan W, Holmes C, Harris S et al (2013) Inflammatory components in human Alzheimer's disease and after active amyloid-beta42 immunization. Brain 136(Pt 9):2677&#x2013;2696.</Citation><ArticleIdList><ArticleId IdType="pubmed">23943781</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>